MidDiagnosed 2026-09-16 13:31:08 KSTNNVSAI Stock Diagnostic ReportNovartis scraps ALS therapy after mid-stage trial setback[OR] Novartis has discontinued development of ALS treatment VHB937 following the failure of a mid-stage clinical trial, which is negatively affecting its share price.View Source Article ↗ AI CATALYST SCORE45 / 100Score computed by Sentinel V12REFERENCE PRICENot measuredReference entry price at analysis time 👍 0🔥 0🤔 0🔗 0𝕏f🔗📤